RS50857B - Konjugati polimera neublastina i postupci za njihovu upotrebu - Google Patents

Konjugati polimera neublastina i postupci za njihovu upotrebu

Info

Publication number
RS50857B
RS50857B YUP-610/03A YUP61003A RS50857B RS 50857 B RS50857 B RS 50857B YU P61003 A YUP61003 A YU P61003A RS 50857 B RS50857 B RS 50857B
Authority
RS
Serbia
Prior art keywords
neublastin
methods
same
polymer conjugates
amino acid
Prior art date
Application number
YUP-610/03A
Other languages
English (en)
Inventor
Dinah W.Y. Sah
Blake R. Pepinsky
Paula Ann Borjack-Sjodin
Stephan S. Miller
Anthony Rossomando
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of YU61003A publication Critical patent/YU61003A/sh
Publication of RS50857B publication Critical patent/RS50857B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)

Abstract

Polipeptid koji sadrži aminokiselinsku sekvencu koja je najmanje 90% identična aminokiselinama 8 -113 SEQ ID Br.:1, naznačen time što taj polipeptid obuhvata aminokiselinu različitu od asparagina u poziciji koja odgovara poziciji 95 u SEQ ID Br.:1, gde aminokiselina supstituisana u u poziciji koja odgovara poziciji 95 uvodi mesto na kome je moguće da se polialkilen glikol veže za polipeptid. Prijava sadrži još 12 nezavisnih i 9 zavisnih patentnih zahteva.
YUP-610/03A 2001-02-01 2002-01-25 Konjugati polimera neublastina i postupci za njihovu upotrebu RS50857B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01

Publications (2)

Publication Number Publication Date
YU61003A YU61003A (sh) 2006-05-25
RS50857B true RS50857B (sr) 2010-08-31

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-610/03A RS50857B (sr) 2001-02-01 2002-01-25 Konjugati polimera neublastina i postupci za njihovu upotrebu

Country Status (36)

Country Link
EP (2) EP1862475A1 (sr)
JP (2) JP4259868B2 (sr)
KR (2) KR100960063B1 (sr)
CN (1) CN1500095B (sr)
AR (1) AR035077A1 (sr)
AT (1) ATE365748T1 (sr)
AU (1) AU2002247037B2 (sr)
BG (1) BG66393B1 (sr)
BR (1) BR0206852A (sr)
CA (1) CA2436407C (sr)
CY (1) CY1106886T1 (sr)
CZ (1) CZ20032080A3 (sr)
DE (1) DE60220879T2 (sr)
DK (1) DK1355936T3 (sr)
EA (1) EA009771B1 (sr)
EE (1) EE05537B1 (sr)
ES (1) ES2289091T3 (sr)
GE (1) GEP20063916B (sr)
HK (1) HK1057759A1 (sr)
HU (1) HU228973B1 (sr)
IL (2) IL156941A0 (sr)
IS (1) IS2867B (sr)
MX (1) MXPA03006805A (sr)
MY (1) MY143685A (sr)
NO (1) NO332150B1 (sr)
NZ (1) NZ527863A (sr)
PL (1) PL211162B1 (sr)
PT (1) PT1355936E (sr)
RS (1) RS50857B (sr)
SG (1) SG149685A1 (sr)
SI (1) SI1355936T1 (sr)
SK (1) SK288123B6 (sr)
TR (1) TR200301208T2 (sr)
UA (2) UA100967C2 (sr)
WO (1) WO2002060929A2 (sr)
ZA (1) ZA200305733B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
WO2002060929A2 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Polymer conjugates of neublastin and methods of using same
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1395279B1 (en) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
HUE028163T2 (en) * 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and their use
EA008743B1 (ru) * 2003-01-31 2007-08-31 Байоджен Айдек Ма Инк. Полимерные конъюгаты мутантного неубластина
NZ574121A (en) 2003-04-18 2011-06-30 Biogen Idec Inc Polyethylene glycol-conjugated gylcosylated neublastin and uses thereof for treatment of pain
BRPI0411243A (pt) 2003-06-10 2006-07-11 Nsgene As método de produzir um polipeptìdio de neublastina biologicamente ativo, ácido nucléico, vetor de expressão, composição farmacêutica, célula, linha de células de compactação, mamìfero não-humano transgênico, dispositivo de cultura de células implantável, uso do vetor, método de tratar uma doença do sistema nervoso, e, polipetìdio de neublastina
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
NZ553431A (en) 2004-08-19 2010-04-30 Biogen Idec Inc Neublastin variants with decreased heparin binding
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
JP2010503630A (ja) 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体
EP2142205B1 (en) * 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
PL2773438T5 (pl) * 2011-11-02 2022-01-17 F.Hoffmann-La Roche Ag Chromatografia przeciążenia i elucji
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
AU2354600A (en) * 1998-12-09 2000-06-26 Amgen, Inc. Grnf4 a neurotrophic factor
WO2002060929A2 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Polymer conjugates of neublastin and methods of using same

Also Published As

Publication number Publication date
EA200300852A1 (ru) 2004-06-24
NO20033441D0 (no) 2003-08-01
IL156941A (en) 2008-11-03
DK1355936T3 (da) 2007-10-29
EE200300355A (et) 2003-10-15
CA2436407A1 (en) 2002-08-08
EE05537B1 (et) 2012-04-16
SI1355936T1 (sl) 2007-12-31
HK1057759A1 (en) 2004-04-16
EP1355936A2 (en) 2003-10-29
PL211162B1 (pl) 2012-04-30
EA009771B1 (ru) 2008-04-28
IS2867B (is) 2014-02-15
MXPA03006805A (es) 2003-11-13
CY1106886T1 (el) 2012-09-26
PL372101A1 (en) 2005-07-11
GEP20063916B (en) 2006-09-11
EP1862475A1 (en) 2007-12-05
JP2009039135A (ja) 2009-02-26
BG108111A (bg) 2004-12-30
ES2289091T3 (es) 2008-02-01
YU61003A (sh) 2006-05-25
CN1500095B (zh) 2010-06-16
ATE365748T1 (de) 2007-07-15
CZ20032080A3 (cs) 2003-10-15
UA82983C2 (ru) 2008-06-10
SK9712003A3 (en) 2004-01-08
EP1355936B1 (en) 2007-06-27
IS6879A (is) 2003-07-17
WO2002060929A2 (en) 2002-08-08
TR200301208T2 (tr) 2005-05-23
CN1500095A (zh) 2004-05-26
KR100960063B1 (ko) 2010-05-31
NO20033441L (no) 2003-10-01
HUP0500637A2 (hu) 2005-09-28
AR035077A1 (es) 2004-04-14
DE60220879T2 (de) 2008-03-06
IL156941A0 (en) 2004-02-08
BG66393B1 (bg) 2013-11-29
UA100967C2 (ru) 2013-02-25
JP4423338B2 (ja) 2010-03-03
SK288123B6 (sk) 2013-09-03
WO2002060929A3 (en) 2003-03-06
AU2002247037B2 (en) 2007-08-16
NO332150B1 (no) 2012-07-09
NZ527863A (en) 2006-09-29
SG149685A1 (en) 2009-02-27
KR20080098662A (ko) 2008-11-11
CA2436407C (en) 2011-08-30
MY143685A (en) 2011-06-30
KR20030074766A (ko) 2003-09-19
PT1355936E (pt) 2007-09-28
HUP0500637A3 (en) 2010-01-28
HU228973B1 (en) 2013-07-29
BR0206852A (pt) 2005-05-03
JP4259868B2 (ja) 2009-04-30
DE60220879D1 (de) 2007-08-09
JP2005503763A (ja) 2005-02-10
ZA200305733B (en) 2005-02-23
KR100872807B1 (ko) 2008-12-09

Similar Documents

Publication Publication Date Title
RS50857B (sr) Konjugati polimera neublastina i postupci za njihovu upotrebu
DE60144145D1 (de) Subtilisin-variante
LU91680I2 (fr) "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)"
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
ATE444756T1 (de) Zusammensetzungen umfassend komplexe von tocopherolphosphatderivaten
BR0110421A (pt) Polipeptìdeos anti-angiogênicos e métodos para inibir a angiogênese
NO20043419L (no) Nytt cytokin, zcytor17-ligand
ATE246202T1 (de) Gcsf konjugate
DK1346034T3 (da) von Willebrand-faktor (vWF) spaltende protease-polypeptid, nukleinsyre kodende for polypeptidet og anvendelse af polypeptidet
DE69528061T2 (de) Gereinigte polyporus laccasen und dafür kodierende nukleinsäuren
RS51898B (sr) Specifični agensi koji vezuju humani angiopoetin-2
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
BR0012759A (pt) Neurotoxinas recombinantes ativáveis
RS50926B (sr) Upotreba il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
RS49517B (sr) PEPTID p277-ANALOZI I FARMACEUTSKI PREPARATI KOJI GA SADRZE
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c
IS6678A (is) Hvarfefni og prófanir fyrir ß-sekretasavirkni
RS50831B (sr) Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid
DE69737476D1 (de) Neuer galaninrezeptor
BR9711540A (pt) Inibidores de protease proteìnico estabilizados e variantes dos mesmos
ES2160978T3 (es) Composiciones farmaceuticas estabilizadas y procedimiento para su preparacion.
SE9904404D0 (sv) Novel composition
ATE385805T1 (de) Neue peptide
EA200000531A1 (ru) Применение кетолидов для профилактики тромботических артериальных осложнений, связанных с атеросклерозом